United Therapeutics CORP Form 4 insider transactions

United Therapeutics Corp's President and COO, Michael Benkowitz, executed pre-planned stock option exercises and subsequent sales of common stock totaling 22,500 shares.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, executed pre-planned stock option exercises and subsequent sales of common stock in early December 2025.

United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock totaling 8,000 shares over two days.

United Therapeutics CFO James Edgemond executed a pre-planned sale of 21,000 common shares following the exercise of stock options.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised stock options and sold common stock shares in pre-arranged transactions.

United Therapeutics' President and COO, Michael Benkowitz, exercised stock options and subsequently sold common stock shares through a pre-arranged 10b5-1 trading plan.

United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock in late November 2025.

United Therapeutics CFO James Edgemond exercised 21,000 stock options and subsequently sold 21,000 common shares under a pre-arranged 10b5-1 plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and subsequently sold 22,500 shares of common stock for approximately $473.66 per share.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, executed pre-arranged sales of common stock and exercised options in late November 2025.

United Therapeutics CEO Martine A. Rothblatt exercised stock options and sold common stock on November 20 and 21, 2025, under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, exercised stock options and sold common stock shares as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics President and COO Michael Benkowitz exercised options and sold 22,500 shares under a Rule 10b5-1 plan on 11/17/2025.

CFO James Edgemond exercised 21,000 options at $146.03 and sold all resulting shares at ~$464–$476 under a 10b5-1 plan, maintaining 8,118 direct shares and 21,517 options outstanding.

CEO Martine Rothblatt exercised options at $120.26 and sold 8,000 shares on Nov. 14 and Nov. 17, 2025 under a pre-set Rule 10b5-1 plan.

United Therapeutics Chairperson & CEO Martine Rothblatt exercised stock options and sold 8,000 common shares under a pre-arranged 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold 11,000 shares of common stock on November 13, 2025, under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock under a pre-arranged 10b5-1 trading plan on November 10 and 11, 2025.

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned stock option exercises and subsequent sales of common stock totaling 22,500 shares.

United Therapeutics CFO James Edgemond exercised stock options and sold 21,000 shares of common stock for over $446 per share under a pre-arranged trading plan.

United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options and sold common stock totaling 8,000 shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock totaling 8,000 shares over two days in November 2025, pursuant to a pre-arranged 10b5-1 trading plan.

United Therapeutics CFO James Edgemond exercised stock options and subsequently sold 21,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock totaling 8,000 shares across two dates in late October and early November 2025, pursuant to a pre-arranged 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, exercised stock options and subsequently sold common stock shares totaling over $10 million, all under a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Christopher Causey reported gifting 450 shares of common stock, reducing his direct beneficial ownership to 4,190 shares.

United Therapeutics CEO Martine Rothblatt discloses planned future stock option exercises and sales under a 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold 11,000 shares under a pre-arranged 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised stock options and sold common stock on October 27 and 28, 2025, under a pre-arranged 10b5-1 trading plan.